Indian stocks: Visit www.stage2stocks.com →

Entrada Therapeutics, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Entrada Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 21, 2026). It closed at $4.73, 70.5% below its 52-week high and below its 200-day average, which is falling.

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have… More about the company

$4.73
+1.72% today
$184M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is TRDA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 36w
S2 23w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 5w → S3 8w → S2 3w → S3 1w → S4 1w → S3 2w → S2 2w → S1 1w → S4 2w → S3 2w → S2 1w → S1 1w → S4 11w → S1 5w → S2 13w → S3 3w → S2 12w → S3 4w → S4 36w → S1 7w → S2 23w → S3 5w → S4 8w → S1 5w → S4 5w current
Total tracked: 163 weeks across 25 stage runs.

TRDA among Biotechnology267th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…267TRDAStage 4 · wk 536−27.2%
vs 52W High
-70.5%
$4.37 lo$16.03 hi
70.5% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 5
1w13w26w
Week 5, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-47.1%
200 DMA: $8.94 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
1.45x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-27.2%
3M
-19.1%
6M
-63.1%
YTD
-52.9%
1Y
-25.6%
Scan Membership
Breakout Watch
Latest: 2024-10-21
7 appearances in last 60 days. First seen: 2022-09-02.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 5 · Vol 1.45x
2026-10-21S4
Wk 5 · Vol 0.81x
2026-10-20S4
Wk 5 · Vol 1.26x
2026-10-19S4
Wk 5 · Vol 1.85x
2026-10-16S4
Wk 4 · Vol 1.18x
2026-10-15S4
Wk 4 · Vol 1.63x
2026-10-14S4
Wk 4 · Vol 2.36x
2026-10-13S4
Wk 4 · Vol 0.80x
2026-10-12S4
Wk 4 · Vol 0.62x
2026-10-09S4
Wk 3 · Vol 0.63x
2026-10-08S4
Wk 3 · Vol 1.09x
2026-10-07S4
Wk 3 · Vol 0.89x
Moving averages & range
50 DMA
$6.40
200 DMA
$8.94
52W High
$16.03
52W Low
$4.37
5D Low
$4.37
Resistance levels (recent highs)
20d High
$6.35
60d High
$7.78
120d High
$16.03
250d High
$16.03
Next resistance
+34.2%
to 20d High
ROE
-54.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.7

Entrada Therapeutics: quick answers

What stage is Entrada Therapeutics in?

As of Oct 22, 2026, Entrada Therapeutics (TRDA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 21, 2026 and is in week 5. What the four stages mean

Is Entrada Therapeutics in an uptrend?

No. Entrada Therapeutics is in a Stage 4 downtrend. It trades 47.1% below its 200-day average, which is falling.

How far is Entrada Therapeutics from its 52-week high?

Entrada Therapeutics closed at $4.73 on Oct 22, 2026, 70.5% below its 52-week high of $16.03. Its 52-week low is $4.37.

How has Entrada Therapeutics performed over the past year?

As of Oct 22, 2026, Entrada Therapeutics is down 25.6% over the past year and down 52.9% so far in 2026.

Which sector and industry is Entrada Therapeutics in?

Entrada Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.